PUBLISHER: KBV Research | PRODUCT CODE: 1395765
PUBLISHER: KBV Research | PRODUCT CODE: 1395765
Europe Myasthenia Gravis Treatment Market Size, Share & Industry Trends Analysis Report By End-use (Hospitals, Clinics and Others), By Type, By Country and Growth Forecast, 2023 - 2030
The Europe Myasthenia Gravis Treatment Market would witness market growth of 9.0% CAGR during the forecast period (2023-2030).
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue due to a breakdown in communication between nerves and muscles at the neuromuscular junction. This condition presents challenges in muscle movement, impacting various daily activities, and often requires long-term management to maintain a reasonable quality of life for patients. While MG is considered a rare disease, the number of diagnosed cases is increasing due to improved awareness, diagnostic techniques, and access to healthcare services. This rising prevalence is expanding the potential patient pool and driving the adoption of treatments.
Advances in diagnostic tools, including blood tests and neuroimaging, have led to more accurate and timely MG diagnosis. Earlier diagnosis encourages the prompt initiation of treatment, enhancing patient outcomes. Improved access to healthcare services, mainly specialized neuromuscular clinics and centres, facilitates the diagnosis and treatment of MG. Patients have greater access to expert care, including neurologists and immunologists experienced in managing MG. Advocacy groups and organizations for MG patients are critical in spreading awareness about the disease and the need for early treatment.
Europe has a growing aging population, leading to increased healthcare needs. Spending on healthcare increases because older people typically need more medical services, such as long-term care and treatments for chronic illnesses. European countries have been investing in innovative healthcare technologies and infrastructure. These investments aim to improve patient care, enhance diagnostics, and streamline administrative processes. Thus, growing healthcare expenditure in many countries of Europe is expected to boost the demand in the region.
The Germany market dominated the Europe Myasthenia Gravis Treatment Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $240.1 Million by 2030. The UK market is exhibiting a CAGR of 8.1% during (2023 - 2030). Additionally, The France market would experience a CAGR of 9.8% during (2023 - 2030).
Based on End-use, the market is segmented into Hospitals, Clinics and Others. Based on Type, the market is segmented into Monoclonal Antibodies, Thymectomy, Cholinesterase Inhibitors, Chronic Immunomodulators, Rapid Immunotherapies and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), Octapharma AG, Novartis AG, Pfizer, Inc., Allergan PLC (AbbVie, Inc.), F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Bausch Health Companies Inc., Kedrion S.p.A, and Zydus Lifesciences Ltd.
Scope of the Study
Market Segments covered in the Report:
By End-use
- Hospitals
- Clinics
- Others
By Type
- Monoclonal Antibodies
- Thymectomy
- Cholinesterase Inhibitors
- Chronic Immunomodulators
- Rapid Immunotherapies
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
- Octapharma AG
- Novartis AG
- Pfizer, Inc.
- Allergan PLC (AbbVie, Inc.)
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC (GSK)
- Bausch Health Companies Inc.
- Kedrion S.p.A
- Zydus Lifesciences Ltd.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Myasthenia Gravis Treatment Market, by End-use
- 1.4.2 Europe Myasthenia Gravis Treatment Market, by Type
- 1.4.3 Europe Myasthenia Gravis Treatment Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market at a Glance
- 2.1 Key Highlights
Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.1.1 Overview
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.3 Porter Five Forces Analysis
Chapter 4. Europe Myasthenia Gravis Treatment Market by End-use
- 4.1 Europe Hospitals Market by Country
- 4.2 Europe Clinics Market by Country
- 4.3 Europe Others Market by Country
Chapter 5. Europe Myasthenia Gravis Treatment Market by Type
- 5.1 Europe Monoclonal Antibodies Market by Country
- 5.2 Europe Thymectomy Market by Country
- 5.3 Europe Cholinesterase Inhibitors Market by Country
- 5.4 Europe Chronic Immunomodulators Market by Country
- 5.5 Europe Rapid Immunotherapies Market by Country
- 5.6 Europe Others Market by Country
Chapter 6. Europe Myasthenia Gravis Treatment Market by Country
- 6.1 Germany Myasthenia Gravis Treatment Market
- 6.1.1 Germany Myasthenia Gravis Treatment Market by End-use
- 6.1.2 Germany Myasthenia Gravis Treatment Market by Type
- 6.2 UK Myasthenia Gravis Treatment Market
- 6.2.1 UK Myasthenia Gravis Treatment Market by End-use
- 6.2.2 UK Myasthenia Gravis Treatment Market by Type
- 6.3 France Myasthenia Gravis Treatment Market
- 6.3.1 France Myasthenia Gravis Treatment Market by End-use
- 6.3.2 France Myasthenia Gravis Treatment Market by Type
- 6.4 Russia Myasthenia Gravis Treatment Market
- 6.4.1 Russia Myasthenia Gravis Treatment Market by End-use
- 6.4.2 Russia Myasthenia Gravis Treatment Market by Type
- 6.5 Spain Myasthenia Gravis Treatment Market
- 6.5.1 Spain Myasthenia Gravis Treatment Market by End-use
- 6.5.2 Spain Myasthenia Gravis Treatment Market by Type
- 6.6 Italy Myasthenia Gravis Treatment Market
- 6.6.1 Italy Myasthenia Gravis Treatment Market by End-use
- 6.6.2 Italy Myasthenia Gravis Treatment Market by Type
- 6.7 Rest of Europe Myasthenia Gravis Treatment Market
- 6.7.1 Rest of Europe Myasthenia Gravis Treatment Market by End-use
- 6.7.2 Rest of Europe Myasthenia Gravis Treatment Market by Type
Chapter 7. Company Profiles
- 7.1 AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Regional Analysis
- 7.1.4 Research & Development Expenses
- 7.1.5 Recent strategies and developments:
- 7.1.5.1 Approval and Trails:
- 7.1.6 SWOT Analysis
- 7.2 Octapharma AG
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Research & Development Expenses
- 7.3 Novartis AG
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Segmental and Regional Analysis
- 7.3.4 Research & Development Expense
- 7.3.5 SWOT Analysis
- 7.4 Pfizer, Inc.
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Regional & Segmental Analysis
- 7.4.4 Research & Development Expense
- 7.4.5 Recent strategies and developments:
- 7.4.5.1 Approval and Trails:
- 7.4.6 SWOT Analysis
- 7.5 Allergan PLC (AbbVie, Inc.)
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Regional Analysis
- 7.5.1 Research & Development Expense
- 7.5.2 SWOT Analysis
- 7.6 F. Hoffmann-La Roche Ltd.
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Segmental and Regional Analysis
- 7.6.4 Research & Development Expense
- 7.6.5 SWOT Analysis
- 7.7 GlaxoSmithKline PLC (GSK)
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Regional Analysis
- 7.7.4 Research & Development Expense
- 7.7.5 SWOT Analysis
- 7.8 Bausch Health Companies Inc
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expenses
- 7.8.5 SWOT Analysis
- 7.9 Kedrion S.p.A
- 7.9.1 Company Overview
- 7.9.2 Financial Analysis
- 7.9.3 Research & Development Expenses
- 7.9.4 SWOT Analysis
- 7.10. Zydus Lifesciences Ltd.
- 7.10.1 Company Overview
- 7.10.2 Financial Analysis
- 7.10.3 Segmental and Regional Analysis
- 7.10.4 Research & Development Expense
- 7.10.5 SWOT Analysis
LIST OF TABLES
- TABLE 1 Europe Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
- TABLE 2 Europe Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
- TABLE 3 Europe Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
- TABLE 4 Europe Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
- TABLE 5 Europe Hospitals Market by Country, 2019 - 2022, USD Million
- TABLE 6 Europe Hospitals Market by Country, 2023 - 2030, USD Million
- TABLE 7 Europe Clinics Market by Country, 2019 - 2022, USD Million
- TABLE 8 Europe Clinics Market by Country, 2023 - 2030, USD Million
- TABLE 9 Europe Others Market by Country, 2019 - 2022, USD Million
- TABLE 10 Europe Others Market by Country, 2023 - 2030, USD Million
- TABLE 11 Europe Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
- TABLE 12 Europe Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
- TABLE 13 Europe Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
- TABLE 14 Europe Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
- TABLE 15 Europe Thymectomy Market by Country, 2019 - 2022, USD Million
- TABLE 16 Europe Thymectomy Market by Country, 2023 - 2030, USD Million
- TABLE 17 Europe Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
- TABLE 18 Europe Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
- TABLE 19 Europe Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
- TABLE 20 Europe Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
- TABLE 21 Europe Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
- TABLE 22 Europe Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
- TABLE 23 Europe Others Market by Country, 2019 - 2022, USD Million
- TABLE 24 Europe Others Market by Country, 2023 - 2030, USD Million
- TABLE 25 Europe Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
- TABLE 26 Europe Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
- TABLE 27 Germany Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
- TABLE 28 Germany Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
- TABLE 29 Germany Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
- TABLE 30 Germany Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
- TABLE 31 Germany Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
- TABLE 32 Germany Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
- TABLE 33 UK Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
- TABLE 34 UK Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
- TABLE 35 UK Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
- TABLE 36 UK Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
- TABLE 37 UK Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
- TABLE 38 UK Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
- TABLE 39 France Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
- TABLE 40 France Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
- TABLE 41 France Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
- TABLE 42 France Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
- TABLE 43 France Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
- TABLE 44 France Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
- TABLE 45 Russia Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
- TABLE 46 Russia Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
- TABLE 47 Russia Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
- TABLE 48 Russia Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
- TABLE 49 Russia Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
- TABLE 50 Russia Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
- TABLE 51 Spain Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
- TABLE 52 Spain Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
- TABLE 53 Spain Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
- TABLE 54 Spain Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
- TABLE 55 Spain Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
- TABLE 56 Spain Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
- TABLE 57 Italy Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
- TABLE 58 Italy Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
- TABLE 59 Italy Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
- TABLE 60 Italy Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
- TABLE 61 Italy Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
- TABLE 62 Italy Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
- TABLE 63 Rest of Europe Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
- TABLE 64 Rest of Europe Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
- TABLE 65 Rest of Europe Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
- TABLE 66 Rest of Europe Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
- TABLE 67 Rest of Europe Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
- TABLE 68 Rest of Europe Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
- TABLE 69 KEY INFORMATION - ASTRAZENECA PLC
- TABLE 70 Key Information - Octapharma AG
- TABLE 71 Key Information - Novartis AG
- TABLE 72 Key Information - Pfizer, Inc.
- TABLE 73 Key Information - Allergan PLC
- TABLE 74 Key Information - F. Hoffmann-La Roche Ltd.
- TABLE 75 Key Information - GlaxoSmithKline PLC
- TABLE 76 Key Information - Bausch Health Companies Inc
- TABLE 77 key Information - Kedrion S.p.A
- TABLE 78 Key Information - Zydus Lifesciences Ltd.
